110115-07-6
Calpain inhibitor II
CAS: 110115-07-6
Molecular Formula: C19H35N3O4S
110115-07-6 - Names and Identifiers
110115-07-6 - Physico-chemical Properties
| Molecular Formula | C19H35N3O4S |
| Molar Mass | 401.56 |
| Density | 1.076±0.06 g/cm3(Predicted) |
| Boling Point | 676.5±55.0 °C(Predicted) |
| Solubility | ethanol: 20mg/mL |
| Appearance | powder |
| Color | white |
| pKa | 13.32±0.46(Predicted) |
| Storage Condition | -20°C |
| MDL | MFCD00065506 |
| In vivo study | ALLM (Calpain inhibitor II) (0.5 mg/kg) is injected every 24 h for 5 days after SCI and inhibits the activation of calpain but not that of caspase 3. ALLM prevents this neuronal cell death. ALLM (0.05-2.5 mg/kg; i.p.; every 24 h for 1 week) reduces motor disturbances after spinal cord injury (SCI). Animal Model: Adult male Wistar rats (280-300g) (spinal cord injury model) Dosage: 0.05, 0.5, and 2.5 mg/kg Administration: Intraperitoneally; every 24 h for 1 week Result: Showed significantly better motor function. |
110115-07-6 - Risk and Safety
| Safety Description | S22 - Do not breathe dust. S24/25 - Avoid contact with skin and eyes. |
| WGK Germany | 3 |
| FLUKA BRAND F CODES | 3-10 |
110115-07-6 - Reference Information
| biological activity | ALLM (Calpain inhibitor II) is a potent inhibitor of calpain (calpain) and cathepsin (cathepsin). ALLM inhibits neuronal death and improves chronic neurological function after spinal cord injury (SCI). |
| in vivo study | ALLM (Calpain inhibitor II) (0.5 mg/kg) is injected every 24 h for 5 days after SCI and inhibits the activation of calpain but not that of caspase 3. ALLM prevents this neuronal cell death. ALLM (0.05-2.5 mg/kg; I. p.; every 24 h for 1 week) reduces motor disturbances after spinal cord injury (SCI). Animal Model: Adult Male Wistar Rats (280-300g) (spinal cord injury model) Dosage: 0.05, 0.5, and 2.5 mg/kg Administration: Intraperitoneally; Every 24 h for 1 week Result: showed significantly better motor function. |
| Animal Model: | Adult male Wistar rats (280-300g) (spinal cord injury model) |
| Dosage: | 0.05, 0.5, and 2.5 mg/kg |
| Administration: | Intraperitoneally; every 24 h for 1 week |
| Result: | Showed significantly better motor function. |
Last Update：2024-04-09 21:54:55
